Pharmacological approach to diabetic macular edema

F. Bandello, G. Casalino, A. Loewenstein, M. Goldstein, D. Pelayes, M. Battaglia Parodi

Research output: Contribution to journalReview articlepeer-review


Diabetic macular edema (DME) is a highly prevalent cause of vision loss and has a remarkable impact on public health, and on the quality of life of diabetic patients. Even though laser photocoagulation has been the standard of care for decades, a substantial group of patients are unresponsive and fail to improve after laser treatment. Recently, new pharmacological approaches based on the use of intravitreal drugs, such as corticosteroids and anti-vascular endothelial growth factor, have revolutionized the treatment of DME. The use of intravitreal drugs is supported by the improvement in visual acuity reported by several clinical trials and can limit the potentially destructive effects of the laser treatment. Encouraging results also emerged from studies evaluating the use of a combination therapy, or the association of intravitreal drugs and laser treatment. This review aims at providing a brief synopsis of the main investigations regarding the current pharmacological approach to DME.

Original languageEnglish
Pages (from-to)88-95
Number of pages8
JournalOphthalmic Research
Issue number2
StatePublished - Jan 2014


  • Anti-vascular endothelial growth factor
  • Corticosteroids
  • Diabetic macular edema


Dive into the research topics of 'Pharmacological approach to diabetic macular edema'. Together they form a unique fingerprint.

Cite this